Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 8254797, 12 pages
http://dx.doi.org/10.1155/2016/8254797
Research Article

Interleukin-22 Might Act as a Double-Edged Sword in Type 2 Diabetes and Coronary Artery Disease

1Department of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China
2Department of Neurology, The Second Affiliated Hospital, Nanjing Medical University, Jiangsu 210029, China

Received 13 April 2016; Accepted 19 July 2016

Academic Editor: Chiara De Luca

Copyright © 2016 Fangchen Gong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M.-A. Cornier, D. Dabelea, T. L. Hernandez et al., “The metabolic syndrome,” Endocrine Reviews, vol. 29, no. 7, pp. 777–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Frostegård, “Immune mechanisms in atherosclerosis, especially in diabetes type 2,” Frontiers in Endocrinology, vol. 4, article 162, 2013. View at Publisher · View at Google Scholar
  3. J. S. Rana, M. Nieuwdorp, J. W. Jukema, and J. J. P. Kastelein, “Cardiovascular metabolic syndrome-an interplay of, obesity, inflammation, diabetes and coronary heart disease,” Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 218–232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. G. K. Hansson, A.-K. L. Robertson, and C. Söderberg-Nauclér, “Inflammation and atherosclerosis,” Annual Review of Pathology, vol. 1, pp. 297–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Huber, P. Sakkinen, C. David, M. K. Newell, and R. P. Tracy, “T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia,” Circulation, vol. 103, no. 21, pp. 2610–2616, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Fabbrini, M. Cella, S. A. McCartney et al., “Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals,” Gastroenterology, vol. 145, no. 2, pp. 366–e3, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Taleb, M. Romain, B. Ramkhelawon et al., “Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis,” The Journal of Experimental Medicine, vol. 206, no. 10, pp. 2067–2077, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Su, H. Lu, H. Jiang et al., “IFN-γ-producing Th17 cells bias by HMGB1-T-bet/RUNX3 axis might contribute to progression of coronary artery atherosclerosis,” Atherosclerosis, vol. 243, no. 2, pp. 421–428, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Ip, N. A. Cilfone, A. C. Belkina et al., “Th17 cytokines differentiate obesity from obesity-associated type 2 diabetes and promote TNFα production,” Obesity, vol. 24, no. 1, pp. 102–112, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Smith, K.-M. R. Prasad, M. Butcher et al., “Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 121, no. 15, pp. 1746–1755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Gisterå, A.-K. L. Robertson, J. Andersson et al., “Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway,” Science Translational Medicine, vol. 5, no. 196, Article ID 196ra100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Dalmas, N. Venteclef, C. Caer et al., “T cell+derived IL-22 amplifies IL-1β+driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes,” Diabetes, vol. 63, no. 6, pp. 1966–1977, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Wang, N. Ota, P. Manzanillo et al., “Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes,” Nature, vol. 514, no. 7521, pp. 237–241, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Ghannam, C. Dejou, N. Pedretti et al., “CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions,” The Journal of Immunology, vol. 186, no. 3, pp. 1411–1420, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. G. L. Stephens, B. Swerdlow, E. Benjamin et al., “IL-9 is a Th17-derived cytokine that limits pathogenic activity in organ-specific autoimmune disease,” European Journal of Immunology, vol. 41, no. 4, pp. 952–962, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Peters, K. D. Fowler, F. Chalmin, D. Merkler, V. K. Kuchroo, and C. Pot, “IL-27 induces Th17 differentiation in the absence of STAT1 signaling,” Journal of Immunology, vol. 195, no. 9, pp. 4144–4153, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Duffaut, A. Zakaroff-Girard, V. Bourlier et al., “Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 10, pp. 1608–1614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Gregersen, M. Skjelland, S. Holm et al., “Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis,” PLoS ONE, vol. 8, no. 8, Article ID e72769, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Fu, Y.-Y. Tang, X.-P. Ouyang et al., “Interleukin-27 inhibits foam cell formation by promoting macrophage ABCA1 expression through JAK2/STAT3 pathway,” Biochemical and Biophysical Research Communications, vol. 452, no. 4, pp. 881–887, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Paneni, J. A. Beckman, M. A. Creager, and F. Cosentino, “Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I,” European Heart Journal, vol. 34, no. 31, pp. 2436–2446, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. P. O. Bonetti, L. O. Lerman, and A. Lerman, “Endothelial dysfunction: a marker of atherosclerotic risk,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 168–175, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Zhao, D. Tang, S. Yi et al., “Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes,” PLoS ONE, vol. 9, no. 1, Article ID e85770, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Zhang, T. Wang, X.-Q. Wang et al., “Elevated frequencies of circulating Th22 cell in addition to Th17 cell and Th17/Th1 cell in patients with acute coronary syndrome,” PLoS ONE, vol. 8, no. 12, Article ID e71466, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. Y.-Z. Lin, B.-W. Wu, Z.-D. Lu et al., “Circulating Th22 and Th9 levels in patients with acute coronary syndrome,” Mediators of Inflammation, vol. 2013, Article ID 635672, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Z. Hasnain, D. J. Borg, B. E. Harcourt et al., “Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress,” Nature Medicine, vol. 20, no. 12, pp. 1417–1426, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Avitabile, T. Odorisio, S. Madonna et al., “Interleukin-22 promotes wound repair in diabetes by improving keratinocyte pro-healing functions,” Journal of Investigative Dermatology, vol. 135, no. 11, pp. 2862–2870, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Rattik, K. Hultman, U. Rauch et al., “IL-22 affects smooth muscle cell phenotype and plaque formation in apolipoprotein E knockout mice,” Atherosclerosis, vol. 242, no. 2, pp. 506–514, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. J. A. Dudakov, A. M. Hanash, and M. R. M. van den Brink, “Interleukin-22: immunobiology and pathology,” Annual Review of Immunology, vol. 33, pp. 747–785, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Zhao, Z. Zhang, Y. Luan et al., “Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment,” Hepatology, vol. 59, no. 4, pp. 1331–1342, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Pastore, F. Mascia, F. Mariotti, C. Dattilo, V. Mariani, and G. Girolomoni, “ERK1/2 regulates epidermal chemokine expression and skin inflammation,” The Journal of Immunology, vol. 174, no. 8, pp. 5047–5056, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Sabat, W. Ouyang, and K. Wolk, “Therapeutic opportunities of the IL-22-IL-22R1 system,” Nature Reviews Drug Discovery, vol. 13, no. 1, pp. 21–38, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat, “IL-22 increases the innate immunity of tissues,” Immunity, vol. 21, no. 2, pp. 241–254, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Xue, D. T. C. Nguyen, and A. Habtezion, “Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis,” Gastroenterology, vol. 143, no. 6, pp. 1670–1680, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Feng, O. Park, S. Radaeva et al., “Interleukin-22 ameliorates cerulein-induced pancreatitis in mice by inhibiting the autophagic pathway,” International Journal of Biological Sciences, vol. 8, no. 2, pp. 249–257, 2012. View at Publisher · View at Google Scholar · View at Scopus